Prelude Therapeutics Inc·4

Feb 17, 7:07 PM ET

Combs Andrew 4

4 · Prelude Therapeutics Inc · Filed Feb 17, 2022

Insider Transaction Report

Form 4
Period: 2022-02-15
Combs Andrew
Chief Chemistry Officer
Transactions
  • Award

    Employee Stock Option (right to buy)

    2022-02-15+100,000100,000 total
    Exercise: $10.58Exp: 2032-02-14Common Stock (100,000 underlying)
Footnotes (1)
  • [F1]The stock option vests as to 25% of the total shares on February 15, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Documents

2 files
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION

  • EX-24

    POA DOCUMENT